3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase NA
2
Status
Completed
8
Unknown
3
Active not recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gynecologic
2
Other neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
387
Breast Neoplasms
368
Colorectal Neoplasms
242
Stomach Neoplasms
220
Carcinoma, Hepatocellular
155
Lung Neoplasms
125
Neoplasms
122
Pancreatic Neoplasms
113
Prostatic Neoplasms
101
Rectal Neoplasms
98
Neoplasm Metastasis
98
Recurrence
92
Ovarian Neoplasms
92
Nasopharyngeal Carcinoma
89
Esophageal Neoplasms
84
Esophageal Squamous Cell Carcinoma
83
Lymphoma, Large B-Cell, Diffuse
79
Melanoma
78
Lymphoma
72
Small Cell Lung Carcinoma
71
Leukemia, Myeloid, Acute
71
Uterine Cervical Neoplasms
70
Brain Neoplasms
70
Sarcoma
69
Squamous Cell Carcinoma of Head and Neck
67
Multiple Myeloma
67
Head and Neck Neoplasms
67
Carcinoma, Renal Cell
65
Triple Negative Breast Neoplasms
63
Colonic Neoplasms
55
Interventions
olaparib
1
niraparib
1
anlotinib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Unknown
×
Genital Diseases, Female
×
Clear all
NCT04556071
2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
32 enrolled
NCT04566952
2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
68 enrolled
NCT02338505
2015-01-14
OB-ALFX
Catholic University of the Sacred Heart
Phase 2
Unknown
50 enrolled